JP2018507860A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507860A5 JP2018507860A5 JP2017544759A JP2017544759A JP2018507860A5 JP 2018507860 A5 JP2018507860 A5 JP 2018507860A5 JP 2017544759 A JP2017544759 A JP 2017544759A JP 2017544759 A JP2017544759 A JP 2017544759A JP 2018507860 A5 JP2018507860 A5 JP 2018507860A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- binding domain
- seq
- protein
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 37
- 150000001413 amino acids Chemical group 0.000 claims 20
- 102000004169 proteins and genes Human genes 0.000 claims 19
- 108090000623 proteins and genes Proteins 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 18
- 230000005945 translocation Effects 0.000 claims 18
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 108020001507 fusion proteins Proteins 0.000 claims 15
- 102000037865 fusion proteins Human genes 0.000 claims 15
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 14
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 claims 13
- 125000000539 amino acid group Chemical group 0.000 claims 11
- 230000011664 signaling Effects 0.000 claims 11
- 244000052769 pathogen Species 0.000 claims 10
- 230000026683 transduction Effects 0.000 claims 10
- 238000010361 transduction Methods 0.000 claims 10
- 230000001717 pathogenic effect Effects 0.000 claims 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 230000001235 sensitizing effect Effects 0.000 claims 7
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims 6
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 6
- 230000004927 fusion Effects 0.000 claims 6
- 230000002163 immunogen Effects 0.000 claims 6
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 6
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims 5
- 230000014759 maintenance of location Effects 0.000 claims 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- 241000711549 Hepacivirus C Species 0.000 claims 4
- 241000701806 Human papillomavirus Species 0.000 claims 4
- 108010066154 Nuclear Export Signals Proteins 0.000 claims 4
- 101710082714 Exotoxin A Proteins 0.000 claims 3
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 claims 3
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 claims 3
- 241000589516 Pseudomonas Species 0.000 claims 3
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 3
- 101150084157 lrp-1 gene Proteins 0.000 claims 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 229930182490 saponin Natural products 0.000 claims 3
- 150000007949 saponins Chemical class 0.000 claims 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 241000700721 Hepatitis B virus Species 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 239000005913 Maltodextrin Substances 0.000 claims 2
- 229920002774 Maltodextrin Polymers 0.000 claims 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 241001673669 Porcine circovirus 2 Species 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 2
- 239000007983 Tris buffer Substances 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 229940035034 maltodextrin Drugs 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 239000001488 sodium phosphate Substances 0.000 claims 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 claims 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 101710132601 Capsid protein Proteins 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 claims 1
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 claims 1
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 claims 1
- 102100037686 Protein SSX2 Human genes 0.000 claims 1
- NKVLDFAVEWLOCX-GUSKIFEASA-N [(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxy-6-methyloxan-2-yl] (4ar,5r,6as,6br,9s,10s,12ar)-10-[(2r,3r,4s, Chemical compound O([C@H]1[C@H](O)CO[C@H]([C@@H]1O)O[C@H]1[C@H](C)O[C@H]([C@@H]([C@@H]1O)O)O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@H]1OC(=O)[C@]12CCC(C)(C)CC1C1=CCC3[C@@]([C@@]1(C[C@H]2O)C)(C)CCC1[C@]3(C)CC[C@@H]([C@@]1(C)C=O)O[C@@H]1O[C@@H]([C@H]([C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)[C@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O)C(=O)NCCCCCCCCCCCC)[C@@H]1OC[C@](O)(CO)[C@H]1O NKVLDFAVEWLOCX-GUSKIFEASA-N 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 101710135378 pH 6 antigen Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562121406P | 2015-02-26 | 2015-02-26 | |
| US62/121,406 | 2015-02-26 | ||
| PCT/US2016/019401 WO2016138164A1 (en) | 2015-02-26 | 2016-02-24 | A vaccine composition comprising an immunogenic protein and combination adjuvants for use in eliciting antigen-specific t-cell responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018507860A JP2018507860A (ja) | 2018-03-22 |
| JP2018507860A5 true JP2018507860A5 (cg-RX-API-DMAC7.html) | 2018-12-20 |
Family
ID=56789742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544759A Pending JP2018507860A (ja) | 2015-02-26 | 2016-02-24 | 抗原特異的ｔ細胞反応を誘発するための、免疫原性タンパク質及びアジュバントの組み合わせを含むワクチン組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9775898B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3261667A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018507860A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20170105107A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107249629A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017018017A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL254110A0 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2017129818A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI674269B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016138164A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019531292A (ja) * | 2016-09-19 | 2019-10-31 | ザヴァックス ジェネティクス ワクチン カンパニー リミテッドＴｈｅｖａｘ Ｇｅｎｅｔｉｃｓ Ｖａｃｃｉｎｅ Ｃｏ．， Ｌｔｄ． | Ｂ型肝炎治療ワクチン |
| WO2019133647A1 (en) * | 2017-12-29 | 2019-07-04 | Thevax Genetics Vaccine Co., Ltd. | Combination of a fusion protein vaccine with anti-ox40 antibody for use in eliciting antigen-specific immune responses |
| CN109134667A (zh) * | 2018-09-19 | 2019-01-04 | 天康生物股份有限公司 | 融合蛋白及其制备方法、应用、表达系统和疫苗 |
| CN109663126A (zh) * | 2019-03-01 | 2019-04-23 | 龙阔（苏州）生物工程有限公司 | 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗 |
| US20210100887A1 (en) * | 2019-10-04 | 2021-04-08 | Reber Genetics Co., Ltd. | Recombinant fusion protein and immunogenic composition |
| CN112972671B (zh) * | 2019-12-13 | 2024-04-19 | 远大赛威信生命科学(南京)有限公司 | 药物组合物及其用途 |
| CN115956086A (zh) * | 2020-05-06 | 2023-04-11 | 萨摩亚商柏沛生医股份有限公司 | 用于针对癌症及传染病的免疫疗法的融合蛋白 |
| CN111548395A (zh) * | 2020-05-25 | 2020-08-18 | 中国农业科学院兰州兽医研究所 | 一种口蹄疫病毒二价多表位重组病毒样颗粒及其应用 |
| CN112626073B (zh) * | 2020-10-26 | 2021-06-15 | 中国科学院昆明动物研究所 | 一种对PRRSV具有特异性免疫刺激作用的CpG-ODN及其应用 |
| WO2023124116A1 (zh) * | 2021-12-28 | 2023-07-06 | 成都迈科康生物科技有限公司 | 一种疫苗佐剂、其制备方法及应用 |
| CN114835822B (zh) * | 2022-04-22 | 2022-11-04 | 浙江洪晟生物科技股份有限公司 | 猪瘟病毒的多聚体疫苗及其制备方法 |
| WO2025180443A1 (en) * | 2024-02-29 | 2025-09-04 | Immunadd Inc. | Adjuvant composition, pharmaceutical composition comprising the same, and method for preventing or treating disease caused by viral infection, bacterial infection, protozoal infection or cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK279188B6 (sk) * | 1992-06-25 | 1998-07-08 | Smithkline Beecham Biologicals S.A. | Vakcínová kompozícia spôsob jej prípravy a použiti |
| US5712149A (en) * | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| PT1104306E (pt) * | 1998-08-10 | 2006-05-31 | Antigenics Inc | Composicoes de cpg e adjuvantes de saponina e seus metodos |
| BRPI0407032A (pt) * | 2003-01-29 | 2006-01-17 | Pfizer Prod Inc | Vacinas caninas contra bordetella bronchiseptica |
| US20060217298A1 (en) * | 2003-02-04 | 2006-09-28 | Srivastava Pramod K | Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins |
| AU2003272065A1 (en) * | 2003-04-03 | 2004-10-25 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof |
| CN101594878A (zh) * | 2006-09-18 | 2009-12-02 | 雷普特药品公司 | 通过给予受体相关蛋白（rap）-缀合物对肝病症的治疗 |
| EP2078726A1 (en) * | 2008-01-09 | 2009-07-15 | Vision 7 GmbH | Secretable HIV entry inhibitory peptides for therapy of HIV infection |
| US20090203884A1 (en) * | 2008-01-31 | 2009-08-13 | Healthbanks Biotech Co., Ltd. | Chimeric hiv fusion proteins as vaccines |
| KR20110050531A (ko) | 2008-08-28 | 2011-05-13 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
| BRPI1013895B1 (pt) * | 2009-04-10 | 2021-08-03 | The Johns Hopkins University | Composições de partícula semelhante a virus (vlp) de virus do papiloma e de capsómero, método de preparação das mesmas, vacina compreendendo a referida composição vlp, polipeptídeo quimérico, kit compreendendo a reverida composição de vlp, bem com usos da referida vlp |
| CA2800774A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
| PL391627A1 (pl) * | 2010-06-25 | 2012-01-02 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| AU2011294244B2 (en) * | 2010-08-26 | 2014-06-12 | Toray Industries, Inc. | Immunogenic composition |
| CN109608550B (zh) * | 2012-12-05 | 2020-09-11 | 生控基因疫苗股份有限公司 | 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白 |
| EP3016685B1 (en) | 2013-07-03 | 2018-01-31 | Visterra, Inc. | Synthetic oligosaccharides for p. aeruginosa vaccine |
| US20150037374A1 (en) * | 2013-07-31 | 2015-02-05 | Csl Limited | Anti-tumor compositions and uses thereof |
| JP2019531292A (ja) * | 2016-09-19 | 2019-10-31 | ザヴァックス ジェネティクス ワクチン カンパニー リミテッドＴｈｅｖａｘ Ｇｅｎｅｔｉｃｓ Ｖａｃｃｉｎｅ Ｃｏ．， Ｌｔｄ． | Ｂ型肝炎治療ワクチン |
-
2016
- 2016-02-24 KR KR1020177023587A patent/KR20170105107A/ko not_active Ceased
- 2016-02-24 JP JP2017544759A patent/JP2018507860A/ja active Pending
- 2016-02-24 WO PCT/US2016/019401 patent/WO2016138164A1/en not_active Ceased
- 2016-02-24 CN CN201680011623.6A patent/CN107249629A/zh active Pending
- 2016-02-24 RU RU2017129818A patent/RU2017129818A/ru not_active Application Discontinuation
- 2016-02-24 US US15/052,713 patent/US9775898B2/en not_active Expired - Fee Related
- 2016-02-24 EP EP16756299.0A patent/EP3261667A4/en not_active Withdrawn
- 2016-02-24 BR BR112017018017A patent/BR112017018017A2/pt not_active IP Right Cessation
- 2016-02-25 TW TW105105741A patent/TWI674269B/zh active
-
2017
- 2017-08-23 IL IL254110A patent/IL254110A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507860A5 (cg-RX-API-DMAC7.html) | ||
| RU2017129818A (ru) | Композиция вакцины, содержащая иммуногенный белок и комбинированные адъюванты, для применения в стимулировании антигенспецифичных т-клеточных ответов | |
| EP2928491B1 (en) | Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses | |
| JP2016199557A5 (cg-RX-API-DMAC7.html) | ||
| JP2016510983A5 (cg-RX-API-DMAC7.html) | ||
| JP2015509707A5 (cg-RX-API-DMAC7.html) | ||
| JP2014530003A5 (cg-RX-API-DMAC7.html) | ||
| JP2016519658A5 (cg-RX-API-DMAC7.html) | ||
| JP2013526849A5 (cg-RX-API-DMAC7.html) | ||
| JP2015212284A5 (cg-RX-API-DMAC7.html) | ||
| ES2790527T3 (es) | Composiciones de vacunas contra el síndrome reproductivo y respiratorio porcino y las enfermedades asociadas al circovirus porcino | |
| JP2021502807A5 (cg-RX-API-DMAC7.html) | ||
| IL274130B1 (en) | HIV–1 vaccine immunogens with novel scaffolds | |
| US20130171182A1 (en) | Influenza vaccine | |
| JP2016520534A5 (cg-RX-API-DMAC7.html) | ||
| JP2020534874A5 (cg-RX-API-DMAC7.html) | ||
| JP2018501258A5 (cg-RX-API-DMAC7.html) | ||
| Shen et al. | Self-adjuvanting lipoimmunogens for therapeutic HPV vaccine development: potential clinical impact | |
| RU2007147938A (ru) | Конъюгаты антигенов и их применение | |
| ES3030310T1 (en) | Sars-cov-2 subunit vaccine | |
| JP2018514512A (ja) | Ｂ型肝炎コア抗原に基づくワクチン | |
| WO2010088393A3 (en) | Li-kay hybrid peptides that modulate the immune response to influenza | |
| CU24751B1 (es) | Antígeno recombinante para la inducción de respuesta inmune contra el virus zika | |
| TH114418A (th) | วัคซีน |